Halper Sadeh Opens Wide-Ranging Shareholder Probes Into New M&A Deals

Overview

• Halper Sadeh launched coordinated probes Monday into a slate of newly announced mergers and sales, citing possible securities-law and fiduciary duty issues.
• The effort spans deals such as Organon’s planned sale to Sun Pharmaceutical for $14 per share, TruBridge’s proposed $26.25-per-share cash sale to Inventurus, and Cyclerion’s merger with Korsana that would leave Cyclerion holders with about 1.5% of the combined company.
• Reviews also cover Kennedy‑Wilson’s $10.90-per-share take-private led by its CEO with Fairfax Financial, Webster’s cash-and-ADS sale to Banco Santander, and transactions involving Brink’s and NCR Atleos.
• The firm warns that insiders may receive special benefits not shared by other investors and says certain deal terms could discourage higher competing bids.
• Halper Sadeh says it may seek higher payouts or added disclosures and, in a separate notice the next day, it opened a probe of Humana insiders, while no lawsuits have been announced.